| |
|
|
|
Westin Boston Waterfront, Boston, MA, USA
May 22-23, 2014
Small molecule drug discovery has approached a critical junction where the rigorous pre-clinical validation and prioritizing of novel targets is of utmost importance. Challenged with thinning development pipelines and significant losses in revenue, greater emphasis is being placed on the stringent selection and validation of targets and candidate molecules to increase success and reduce attrition rates in phase II trials. In response to this challenge, a synergy between drug discovery and chemical biology is emerging as a vital component to providing adequate confidence before launching full discovery programs. The development and utilization of high-quality chemical probes in combination with disease-relevant phenotypic systems provides a powerful approach to obtain a deeper interrogation of target-phenotype relationships - ultimately enriching target validation.
Cambridge Healthtech Institute is proud to announce the Inaugural Chemical Biology for Target Validation conference, established to convene an interdisciplinary collection of leaders in chemical/structural biology, chemical proteomics, medicinal chemistry, synthetic chemistry and chemogenomics to discuss strategies to de-risk novel discovery initiatives.
|
|
|
|
|
|
|
|
Organized by:
|
|
Cambridge Healthtech Institute (CHI) |
|
|
Invited Speakers:
|
|
- Chas Bountra, Ph.D., Professor, Translational Medicine; Head, Structural Genomics Consortium, University of Oxford
- Iván Cornella-Taracido, Ph.D., Head, Chemical Biology; Associate Director, Discovery Sciences Chemistry Innovation Centre, AstraZeneca
- Jeremy L. Jenkins, Ph.D., Senior Investigator I, Developmental & Molecular Pathways, High-Throughput Biology, Novartis Institutes for BioMedical Research
- Guri Nina Giaever, Ph.D., Associate Professor, Faculty of Pharmaceutical Sciences, The University of British Columbia
- Marie-Edith Gourdel, Ph.D., Director, Chemistry, HYBRIGENICS SERVICES
- Lyn Jones, Ph.D., Head, Rare Diseases Chemistry; Head, Chemical Biology, Pfizer
- Haian Fu, Ph.D., Professor, Pharmacology, Hematology & Medical Oncology; Director, Emory Chemical Biology Discovery Center; Director, Discovery & Developmental Therapeutics Program of Winship Cancer Institute, Emory University
- Samy Meroueh, Ph.D., Associate Professor, Biochemistry and Molecular Biology, Indiana University School of Medicine
- Stuart L. Schreiber, Ph.D., Director, Chemical Biology & Founding Member, Broad Institute of Harvard and MIT; Howard Hughes Medical Institute Investigator; Morris Loeb Professor, Chemistry and Chemical Biology, Harvard University
- Rathnam Chaguturu, Ph.D., Senior Director, Discovery Sciences, SRI International
- Nathanael Gray, Ph.D., Professor, Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School; Professor, Cancer Biology, Dana-Farber Cancer Institute
- Eranthie Weerapana, Ph.D., Assistant Professor, Chemistry, Boston College
- Lisa Marcaurelle, Ph.D., Vice President, Discovery Chemistry, H3 Biomedicine
- Derek Tan, Ph.D., Member and Laboratory Head, Molecular Pharmacology & Chemistry Program, Sloan–Kettering Institute for Cancer Research, Memorial Sloan–Kettering Cancer Center
- Litao Zhang, Ph.D., Executive Director, Applied Biotechnology, Lead Evaluation and Mechanistic Biochemistry, Bristol-Myers Squibb
- Steven P. Gygi, Ph.D., Professor, Cell Biology, Harvard Medical School
- Jonathan Carlson, M.D., Ph.D., Instructor, Medicine, MGH Cancer Center; Center for Systems Biology, Massachusetts General Hospital
- Doug Johnson, Ph.D., Associate Research Fellow, Neuroscience, Medicinal Chemistry, Pfizer
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
---
|
|
|
|
|
|
|
|
Registration:
|
|
Register now
|
|
|
E-mail:
|
|
kwaterman@healthtech.com
|
|
|
|
|
|
|
|
|